 DUBLIN, July 7, 2021 PRNewswire -- Mallinckrodt plc OTCMKTS: MNKKQ, a global biopharmaceutical company, today announced publication of results from the pivotal Phase 3 STRATA2016 clinical trial of StrataGraft allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen dsat, which is approved for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated deep partial-thickness burns. The data were published in Burns , a peer-reviewed journal of the International Society for Burn Injuries. 